The FOLFOX regimen (oxaliplatin, leucovorin, and 5-fluorouracil) is FDA approved for use in
patients with colorectal cancer and other gastrointestinal malignancies. The initial phase III …

Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the
standard chemotherapy regimens for treating a colorectal carcinoma. The most common …

Oxaliplatin with 5-fluorouracil plus leucovorin (FOLFOX) has become the standard treatment
in patients with colorectal cancer. Among known toxicities induced by oxaliplatin …

Background: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is
commonly used in the treatment of colorectal cancer and is rarely associated with pulmonary …

Background: Chemotherapy with oxaliplatin and 5-fluorouracil (5-FU)/folinic acid is the
standard first-line therapy of metastatic colorectal carcinoma and has shown activity in …

Oxaliplatin is a third generation platinum compound, which is usually used in combination
with capecitabine or 5 fluorouracil for gastro-intestinal cancers. With Oxaliplatin based …

Oxaliplatin is a common chemotherapy drug, used mainly for colon and gastric cancer. Most
common side effects are peripheral sensory neuropathy, hematological toxicity, and allergic …

Background. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (FOLFOX)
is a common chemotherapeutic regimen for advanced colorectal cancer. Here, we present a …

The combination of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) has recently been
shown to be beneficial in advanced colorectal and gastric cancers. The side effects of this …

Rapidly developing pulmonary fibrosis associated with the use of the anti-cancer drug
oxaliplatin has been reported mainly by Asiatic literature as isolate case reports. This rare …